NS Pharma, Inc. is presenting nonclinical pharmacology data on NS-863, a potential platelet-derived growth factor inhibitor for treating pulmonary arterial hypertension and interstitial lung disease.

NS Pharma, Inc. (NSP) is a biopharmaceutical leader in delivering life-changing care to people living with complex, rare diseases, backed by over 100 years of Nippon Shinyaku Co. development expertise. We commercialize innovative therapies for people living with rare diseases including debilitating genetic disorders, such as Duchenne muscular dystrophy (DMD) and Hunter Syndrome. By leveraging our passionate relationships with patients, caregivers, advocacy groups, and healthcare professionals we strive to address unmet needs, understand the integrated patient journey and seize opportunities for furthering impactful innovation. NSP serves as a contact point for connecting Japan/Asia and the world, developing drug candidates invented in Japan and out-licensing them to the world.